More specifically, in colorectal cancer (CRC) patients, RNAMethyPro-led identification of the high-risk group significantly associated with the mesenchymal subtype, demonstrated activation of EMT and transforming growth factor beta (TGFβ) pathway, increased cancer stemness and higher overall stromal and immune content. The gene discussed is TGFB1; the disease is colorectal carcinoma.